Company Overview
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchairs and other living aids specifically for people with disabilities, the elderly, and individuals recovering from injury. The company operates within the Healthcare sector, specifically the Medical Instruments & Supplies industry, which positions it as a provider of essential assistive devices critical for mobility and daily living support. This entity is characterized by a relatively small scale, with a total market capitalization of $324.84M, an annual revenue of $20.69M, and an employee base of 273. These figures indicate that the company functions as a micro-cap enterprise with limited revenue generation relative to its valuation, suggesting a niche operational footprint rather than broad market dominance. The disparity between the $324.84M market cap and the $20.69M revenue highlights a significant premium investors are placing on the company's future potential or specific assets, despite the modest operational scale indicated by the employee count and current earnings.
Financial Health
The company reported a total revenue of $20.69M for the trailing twelve months, generating a net income of $1.19M and an EBITDA of $851,585. The substantial gap between the $20.69M revenue and the $1.19M net income reveals a cost structure where operating expenses and taxes consume a significant portion of gross earnings before reaching the bottom line. While the EBITDA stands at $851,585, the free cash flow is reported at -$5,111,959, indicating that the company is currently consuming cash rather than generating it from operations. This negative cash flow suggests limited financial flexibility, as the firm must rely on existing cash reserves or external financing to fund its capital expenditures and working capital requirements without immediate revenue contribution. Regarding profitability efficiency, the gross margin stands at 30.2%, the operating margin is 9.8%, and the profit margin is 5.8%, with the lower profit margin relative to the gross margin indicating significant overhead costs or tax impacts reducing the final return to shareholders. On the balance sheet, the company holds $29.63M in cash against $18.91M in debt, resulting in a debt-to-equity ratio of 63.95, which suggests a leveraged position where equity is significantly smaller than the debt obligations. The current ratio of 1.85 indicates a conservative short-term liquidity stance, as the company holds sufficient current assets to cover its current liabilities nearly twice over. Furthermore, the return on equity is 4.8% and the return on assets is 0.8%, revealing that management effectiveness in generating returns is currently low, particularly when viewed through the lens of total asset utilization.
Valuation Assessment
The trailing twelve-month P/E ratio is 10.38, while the forward P/E is listed as N/A, implying that analysts or the market currently lack a reliable forecast for future earnings growth or are unable to project a meaningful earnings multiple. The price-to-book ratio is 0.55, which indicates that the market is valuing the company at less than its book value, suggesting a discount relative to the net asset value recorded on the balance sheet. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 15.70 and an EV/EBITDA of 6.54, where the high P/S multiple contrasts sharply with the low EV/EBITDA, reflecting investor pricing based on revenue potential despite current earnings challenges. The stock has exhibited significant price volatility, trading between a 52-week high of $19.70 and a 52-week low of $2.00. Given the wide range between these two data points, the current trading price sits significantly below the 52-week high, reflecting the recent decline in market sentiment or fundamental performance. The beta value is 9.47, which signifies extreme price volatility relative to the broader market, as the stock is nearly ten times as sensitive to market movements as a standard beta-one asset.
Growth & Income
Recent performance data shows a revenue growth year-over-year of -16.5% and an earnings growth year-over-year of -32.0%. The earnings growth rate is declining at a much faster pace than the revenue growth rate, implying that cost inefficiencies, margin compression, or structural issues are exacerbating the decline in profitability beyond the drop in sales volume. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings rather than distributing them to shareholders. Because the firm is a non-dividend payer, it effectively reinvests its earnings into growth initiatives or maintains its cash position, though the negative free cash flow complicates the ability to fund such internal reinvestment. The overall growth and income profile is characterized by negative revenue and earnings expansion combined with a lack of dividend income, presenting a challenging scenario for income-focused or capital appreciation investors seeking stability.